Tarsus Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tarsus Pharmaceuticals (TARS).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$89Upside to Avg. PT+23.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$116
Sep 16, 2026	Barclays	Glen Santangelo	Reinstates	Overweight	$110
Sep 8, 2026	Jefferies	Anthony Petrone	PT Raise	Buy	$88→$105
Aug 12, 2026	Oppenheimer	Francois Brisebois	PT Raise	Outperform	$97→$100
Jul 31, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$100→$98
Jul 21, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$90→$89
Jul 9, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$88
May 4, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$88
Feb 25, 2026	Oppenheimer	Francois Brisebois	PT Raise	Outperform	$95→$105
Feb 25, 2026	Guggenheim	Eddie Hickman	PT Raise	Buy	$87→$90
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$100
Nov 20, 2025	Mizuho	Graig Suvannavejh	Initiate	Outperform	$100
Nov 5, 2025	Guggenheim	Eddie Hickman	PT Raise	Buy	$84→$87
Oct 20, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$72→$88
May 27, 2025	HC Wainwright & Co.	Matthew Caufield	Assumes	Buy	$72
May 5, 2025	Goldman Sachs	Andrea Tan	PT Raise	Neutral	$46→$51
May 2, 2025	Guggenheim	Eddie Hickman	PT Raise	Buy	$78→$84
Mar 6, 2025	Jefferies	Anthony Petrone	PT Raise	Buy	$54→$58
Feb 26, 2025	Guggenheim	Eddie Hickman	PT Raise	Buy	$75→$78
Feb 26, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Buy	$73

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.

Benzinga Newsdesk

PRO
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $90 to $89.

Benzinga Newsdesk

Tarsus Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Tarsus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

PRO
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

PRO
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

PRO
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

PRO
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

PRO
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

People Also Watch

People Also Watch

Tarsus Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Tarsus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

PROBarclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

PROJefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

PROOppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

PROMizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

PROGuggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

People Also Watch

People Also Watch

PRO
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

PRO
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

PRO
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

PRO
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

PRO
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

PRO
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89